Drug Trial Radar · NCT06426303
Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 2, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Milky KohnoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Portland VA Medical Center
- First posted
- May 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to identify sex-specific biomarkers that confer greater susceptibility for Alcohol Use Disorder (AUD) and differentiate how treatment response varies by sex in people with Alcohol Use Disorder. The main questions it aims to answer are: * How does trauma affect emotion regulation, inflammation, and limbic function, and what are the sex-dependent effects of NTX (Naltrexone) on these aspects? * What is the mechanism of Naltrexone (NTX), and how does it potentially moderate reductions in alcohol use through changes in or interactions between emotion regulation, inflammation, or limbic system function? Participants will * Be consented and will undergo comprehensive screening for eligibility criteria * Complete behavioral assessments and neuropsychological assessments, as well as neurocognitive assessments and neuroimaging measures * Provide urine samples for a urine drug screen (UDS) and urine pregnancy test (for women), and have blood and a cheek swab collected and stored in the repository * Take a study drug once daily for 12 weeks and track drug usage and effects in a study journal * Undergo weekly assessment calls and bi-weekly medical follow-up safety exams Researchers will compare naltrexone to placebo in AUD to see if naltrexone is effective in reducing alcohol cravings and promoting abstinence. Researchers will also compare baseline measures between AUD and Healthy Controls.
Conditions
- Alcohol Use Disorder
Interventions
NaltrexoneDrug
12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in alcohol use (number of drinking days, amount used per day)Time frame: Baseline and Week 12
- Changes from baseline in peripheral immune biomarkers associated with inflammationTime frame: Baseline and Week 12
- Changes in limbic functional connectivityTime frame: Baseline and Week 12
- Changes from baseline in BOLD signal brain activation during an emotion regulation fMRI taskTime frame: Baseline and Week 12
- Changes from baseline in emotion regulation assessed with the Difficulty in Emotion Regulation Scale (DERS)Time frame: Baseline and Week 12
- Changes from baseline in emotion regulation assessed with the Cognitive Emotion Regulation Questionnaire (CERQ)Time frame: Baseline and Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
VA Portland Health Care System
Portland, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.